|
AURKAPS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.08784117666983E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.89639448378421E-13 |
| Normal-vs-Stage2 |
5.46307443727301E-12 |
| Normal-vs-Stage3 |
1.67088565206086E-12 |
| Normal-vs-Stage4 |
2.66586752672993E-12 |
| Stage1-vs-Stage2 |
6.765600E-01 |
| Stage1-vs-Stage3 |
8.549900E-02 |
| Stage1-vs-Stage4 |
7.093800E-01 |
| Stage2-vs-Stage3 |
9.662200E-02 |
| Stage2-vs-Stage4 |
5.146000E-01 |
| Stage3-vs-Stage4 |
4.811200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.92035276569413E-12 |
| Normal-vs-AfricanAmerican |
5.96400040464573E-10 |
| Normal-vs-Asian |
1.30170318968226E-11 |
| Caucasian-vs-AfricanAmerican |
8.952800E-01 |
| Caucasian-vs-Asian |
2.566400E-01 |
| AfricanAmerican-vs-Asian |
5.177200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.7247982476174E-13 |
| Normal-vs-Female |
4.16666701141821E-13 |
| Male-vs-Female |
8.593800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.97428748297079E-13 |
| Normal-vs-Age(41-60Yrs) |
1.45772283133283E-13 |
| Normal-vs-Age(61-80Yrs) |
4.9720227934813E-12 |
| Normal-vs-Age(81-100Yrs) |
5.224700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.975600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.798800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.563000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.812820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.106400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.953800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.7356999999496E-06 |
| Classical-VS-Follicular |
1.171200E-01 |
| Classical-VS-Other |
6.067800E-01 |
| Classical-VS-Normal |
4.88387108532606E-13 |
| Tall-VS-Follicular |
1.155630E-04 |
| Tall-VS-Other |
3.038200E-01 |
| Tall-VS-Normal |
1.55431223447522E-15 |
| Follicular-VS-Other |
1.301560E-01 |
| Follicular-VS-Normal |
1.14089959701857E-10 |
| Other-VS-Normal |
1.33519995060283E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.2263081095607E-13 |
| Normal-vs-N1 |
1.05450093101922E-11 |
| N0-vs-N1 |
6.207200E-01 |
|
|
